ALNY vs. DHR: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ALNY and DHR, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
DHR stands out with 133.69 billion USD in market value—about 3.50× ALNY’s market cap of 38.15 billion USD.
DHR carries a higher beta at 0.83, indicating it’s more sensitive to market moves, while ALNY remains steadier at 0.17.
| Symbol | ALNY | DHR |
|---|---|---|
| Company Name | Alnylam Pharmaceuticals, Inc. | Danaher Corporation |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Medical - Diagnostics & Research |
| CEO | Dr. Yvonne L. Greenstreet M.B.A., M.D. | Mr. Rainer M. Blair |
| Price | 292.58 USD | 186.81 USD |
| Market Cap | 38.15 billion USD | 133.69 billion USD |
| Beta | 0.17 | 0.83 |
| Exchange | NASDAQ | NYSE |
| IPO Date | June 1, 2004 | December 29, 1978 |
| ADR | No | No |
Performance Comparison
This chart compares the performance of ALNY and DHR over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
The section examines key financial ratios to assess the valuation of ALNY and DHR based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.
- ALNY posts a negative P/E of -140.68, reflecting last year’s net loss, while DHR at 35.54 signals healthy earnings.
- ALNY posts a negative forward PEG of -38.16, hinting at anticipated earnings decline, whereas DHR at 3.34 has projections for stable or growing earnings.
- ALNY has a negative Price-to-Free Cash Flow ratio of -506.05, signaling it consumed more cash than it produced over the last year—an important liquidity warning. In contrast, DHR (P/FCF 27.27) indicates positive free cash flow generation.
| Symbol | ALNY | DHR |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | -140.68 | 35.54 |
| Forward PEG Ratio (TTM) | -38.16 | 3.34 |
| Price-to-Sales Ratio (P/S, TTM) | 16.25 | 5.61 |
| Price-to-Book Ratio (P/B, TTM) | 328.68 | 2.63 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | -506.05 | 27.27 |
| EV-to-EBITDA (TTM) | -251.73 | 20.68 |
| EV-to-Sales (TTM) | 16.37 | 6.22 |
| EV-to-Free Cash Flow (TTM) | -509.80 | 30.23 |
Dividend Comparison
ALNY offers a 0% dividend yield, suggesting it may be reinvesting available cash back into the business for future growth, while DHR provides a 0.60% dividend yield, giving investors a steady income stream.
| Symbol | ALNY | DHR |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.60% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of ALNY and DHR, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- ALNY is heavily leveraged (debt-to-equity ratio 11.28), which can boost returns but raises risk if borrowing costs climb, while DHR at 0.32 keeps leverage at a more moderate level.
- With negative EBIT (-0.79), ALNY cannot cover its interest payments. DHR, with an interest coverage of 16.93, meets its interest obligations.
| Symbol | ALNY | DHR |
|---|---|---|
| Current Ratio (TTM) | 3.04 | 1.43 |
| Quick Ratio (TTM) | 2.98 | 1.05 |
| Debt-to-Equity Ratio (TTM) | 11.28 | 0.32 |
| Debt-to-Assets Ratio (TTM) | 0.31 | 0.21 |
| Interest Coverage Ratio (TTM) | -0.79 | 16.93 |